TY - JOUR
T1 - Coronary vasomotor control in obesity and morbid obesity
T2 - Contrasting flow responses with endocannabinoids, leptin, and inflammation
AU - Quercioli, Alessandra
AU - Pataky, Zoltan
AU - Montecucco, Fabrizio
AU - Carballo, Sebastian
AU - Thomas, Aurlien
AU - Staub, Christian
AU - Di Marzo, Vincenzo
AU - Vincenti, Gabriella
AU - Ambrosio, Giuseppe
AU - Ratib, Osman
AU - Golay, Alain
AU - MacH, Franois
AU - Harsch, Elisabetta
AU - Schindler, Thomas H.
N1 - Funding Information:
Supported by research grant nos. 3200B0-122237 (Dr. Schindler) and 32002B-134963 (Dr. Montecucco) from the Swiss National Science Foundation , with contributions of the Clinical Research Center, University Hospital, and Faculty of Medicine, Geneva and the Louis-Jeantet Foundation (Dr. Schindler); Swiss Heart Foundation (Dr. Schindler); the “Sir Jules Thorn Trust Reg” fund and Gustave and Simone Prévot fund (Dr. Montecucco); and fellowship grants from the Novartis Foundation (Dr. Quercioli), and the European Society of Cardiology and the Italian Society of Cardiology (Dr. Vincenti). Dr. Ambrosio has consulted for Menarini International, Merck, Schering-Plough, Angelini, and has served on the Speakers' Bureau for Boehringer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2012/8
Y1 - 2012/8
N2 - This study sought to investigate abnormalities in coronary circulatory function in 2 different disease entities of obese (OB) and morbidly obese (MOB) individuals and to evaluate whether these would differ in severity with different profiles of endocannabinoids, leptin, and C-reactive protein (CRP) plasma levels. There is increasing evidence that altered plasma levels of endocannabinoids, leptin, and CRP may affect coronary circulatory function in OB and MOB. Myocardial blood flow (MBF) responses to cold pressor test from rest and during pharmacologically induced hyperemia were measured with N-13 ammonia positron emission tomography/computed tomography. Study participants (n = 111) were divided into 4 groups based on their body mass index (BMI) (kg/m 2 ): 1) control group (BMI: 20 to 24.9, n = 30); 2) overweight group (BMI: 25 to 29.9, n = 31), 3) OB group (BMI: 30 to 39.9, n = 25); and 4) MOB group (BMI <40, n = 25). The cold pressor testinduced change in endothelium-related MBF response (ΔMBF) progressively declined in overweight and OB groups when compared with the control group [median: 0.19 (interquartile range [IQR] 0.08, 0.27) and 0.11 (0.03, 0.17) vs. 0.27 (0.23, 0.38) ml/g/min; p ≤ 0.01, respectively], whereas it did not differ significantly between OB and MOB groups [median: 0.11 (IQR: 0.03, 0.17) and 0.09 (0.01, 0.19) ml/g/min; p = 0.93]. Compared with control subjects, hyperemic MBF subjects comparably declined in the overweight, OB, and MOB groups [median: 2.40 (IQR 1.92, 2.63) vs. 1.94 (1.65, 2.30), 2.05 (1.67, 2.38), and 2.14 (1.78, 2.76) ml/g/min; p ≤ 0.05, respectively]. In OB individuals, ΔMBF was inversely correlated with increase in endocannabinoid anandamide (r = 0.45, p = 0.044), but not with leptin (r = 0.02, p = 0.946) or with CRP (r = 0.33, p = 0.168). Conversely, there was a significant and positive correlation among ΔMBF and elevated leptin (r = 0.43, p = 0.031) and CRP (r = 0.55, p = 0.006), respectively, in MOB individuals that was not observed for endocannabinoid anandamide (r = 0.07, p = 0.740). Contrasting associations of altered coronary endothelial function with increases in endocannabinoid anandamide, leptin, and CRP plasma levels identify and characterize OB and MOB as different disease entities affecting coronary circulatory function.
AB - This study sought to investigate abnormalities in coronary circulatory function in 2 different disease entities of obese (OB) and morbidly obese (MOB) individuals and to evaluate whether these would differ in severity with different profiles of endocannabinoids, leptin, and C-reactive protein (CRP) plasma levels. There is increasing evidence that altered plasma levels of endocannabinoids, leptin, and CRP may affect coronary circulatory function in OB and MOB. Myocardial blood flow (MBF) responses to cold pressor test from rest and during pharmacologically induced hyperemia were measured with N-13 ammonia positron emission tomography/computed tomography. Study participants (n = 111) were divided into 4 groups based on their body mass index (BMI) (kg/m 2 ): 1) control group (BMI: 20 to 24.9, n = 30); 2) overweight group (BMI: 25 to 29.9, n = 31), 3) OB group (BMI: 30 to 39.9, n = 25); and 4) MOB group (BMI <40, n = 25). The cold pressor testinduced change in endothelium-related MBF response (ΔMBF) progressively declined in overweight and OB groups when compared with the control group [median: 0.19 (interquartile range [IQR] 0.08, 0.27) and 0.11 (0.03, 0.17) vs. 0.27 (0.23, 0.38) ml/g/min; p ≤ 0.01, respectively], whereas it did not differ significantly between OB and MOB groups [median: 0.11 (IQR: 0.03, 0.17) and 0.09 (0.01, 0.19) ml/g/min; p = 0.93]. Compared with control subjects, hyperemic MBF subjects comparably declined in the overweight, OB, and MOB groups [median: 2.40 (IQR 1.92, 2.63) vs. 1.94 (1.65, 2.30), 2.05 (1.67, 2.38), and 2.14 (1.78, 2.76) ml/g/min; p ≤ 0.05, respectively]. In OB individuals, ΔMBF was inversely correlated with increase in endocannabinoid anandamide (r = 0.45, p = 0.044), but not with leptin (r = 0.02, p = 0.946) or with CRP (r = 0.33, p = 0.168). Conversely, there was a significant and positive correlation among ΔMBF and elevated leptin (r = 0.43, p = 0.031) and CRP (r = 0.55, p = 0.006), respectively, in MOB individuals that was not observed for endocannabinoid anandamide (r = 0.07, p = 0.740). Contrasting associations of altered coronary endothelial function with increases in endocannabinoid anandamide, leptin, and CRP plasma levels identify and characterize OB and MOB as different disease entities affecting coronary circulatory function.
KW - 2-AG
KW - 2-arachidonoylglycerol
KW - AEA
KW - ANOVA
KW - BMI
KW - CAC
KW - CAD
KW - CI
KW - CON
KW - CPT
KW - CT
KW - CVR
KW - EC
KW - HDL
KW - MBF
KW - MFR
KW - MOB
KW - OB
KW - OW
KW - PET
KW - RPP
KW - SBP
KW - analysis of variance
KW - anandamide
KW - body mass index
KW - cold pressor test
KW - computed tomography
KW - confidence interval
KW - control subject(s)
KW - coronary artery calcification
KW - coronary artery disease
KW - coronary vascular resistance
KW - endocannabinoid(s)
KW - high-density lipoprotein
KW - high-sensitivity C-reactive protein
KW - hsCRP
KW - morbid obesity
KW - myocardial blood flow
KW - myocardial flow reserve
KW - obesity
KW - overweight
KW - positron emission tomography
KW - rate-pressure product
KW - systolic blood pressure
UR - http://www.scopus.com/inward/record.url?scp=84865079899&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2012.01.020
DO - 10.1016/j.jcmg.2012.01.020
M3 - Article
C2 - 22897994
AN - SCOPUS:84865079899
SN - 1936-878X
VL - 5
SP - 805
EP - 815
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 8
ER -